In corticosteroid-treated rheumatic disease patients, lumbar spine density changed by -0.1% with salmon calcitonin versus -0.2% with placebo, without significant difference.
In plain wordsIn corticosteroid-treated patients, spine density change did not differ significantly between salmon calcitonin and placebo.
- Peptide
- Calcitonin-salmon
- Outcome
- No significant changeLumbar spine density change
- Study
n = 40
- Comparator
- Placebo with calcium and vitamin D3
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 100 IU three times weekly · subcutaneous · 2 yearsAs given in this study (human).
Measurements
- Lumbar spine density change
- −0.1%
- calcitonin
- Lumbar spine density change
- −0.2%
- placebo
Source sentences
The mean within-subject percentage change in DXA lumbar spine density in the two groups over the 2-year period of the study was only -0.1% (calcitonin plus calcium) versus -0.2% (placebo plus calcium) a nonsignificant difference despite the high mean cumulative corticosteroid doses of 5371 mg and 46…
3 context sentences(design, population, supporting numbers)
To assess the efficacy of salmon calcitonin in preventing corticosteroid- induced osteoporosis, 48 patients with newly diagnosed polymyalgia rheumatica, temporal arteritis, and other vasculitides were enrolled in a 2-year, double-blind, randomized, controlled trial.
Patients were randomized to receive subcutaneous injections t.i.w. of either 100 IU of salmon calcitonin (25 patients) or placebo (23 patients).
All patients also received supplemental calcium carbonate (1500 mg daily in divided doses) and vitamin D3 (400 IU daily).